Residual Inflammatory and Cholesterol Risk and the Association With Recurrent Cardiovascular Events in East Asian

Ang Gao1, Tingting Guo2,3, Zhiqiang Yang1

  • 1Department of Cardio-Metabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100006 Beijing, China.

PubMed

Insights

In East Asian patients post-PCI, a lower high-sensitivity C-reactive protein (hs-CRP) cutoff (1.56 mg/L) identifies high inflammatory risk. Persistent inflammation, not cholesterol, predicts major adverse cardiovascular and cerebrovascular events (MACCEs), with hs-CRP being a stronger indicator.

Area of Science:

  • Cardiology
  • Biomarkers
  • Public Health

Background:

  • Established high-risk inflammatory criteria, particularly hypersensitive C-reactive protein (hs-CRP) cutoff values, are not well-validated for East Asian populations.
  • The prognostic significance of cholesterol and inflammation may change post-lipid-lowering treatment in these patients.

Purpose of the Study:

  • To determine a high-risk hs-CRP cutoff value for East Asian patients after percutaneous coronary intervention (PCI).
  • To compare the prognostic value of inflammation versus cholesterol risk in East Asian patients post-PCI.

Main Methods:

  • Retrospective analysis of post-PCI patients with serial hs-CRP and low-density lipoprotein cholesterol (LDL-C) measurements.
  • Major adverse cardiovascular and cerebrovascular events (MACCEs) defined as cardiovascular death, myocardial infarction, stroke, or revascularization.
  • Association between residual risks (cholesterol and inflammation) and MACCEs evaluated.

Main Results:

  • A total of 403 MACCEs occurred in 2373 patients over a median follow-up of 30.4 months.
  • High-risk cutoff values were identified as hs-CRP ≥1.56 mg/L and LDL-C ≥1.80 mmol/L.
  • Residual inflammatory risk (hs-CRP ≥1.56 mg/L) and combined residual risk (hs-CRP ≥1.56 mg/L and LDL-C ≥1.80 mmol/L) significantly predicted MACCEs (HRs 2.15 and 2.07, respectively).
  • Persistent high inflammatory risk was a major determinant of MACCEs (aHR 2.03), while persistent high cholesterol risk was not.
  • Serial hs-CRP measurements provided greater predictive value for MACCEs than single measurements.

Conclusions:

  • A lower hs-CRP cutoff (1.56 mg/L) may be appropriate for identifying high-risk East Asian patients post-PCI.
  • Persistent inflammation, indicated by hs-CRP, is a stronger predictor of MACCEs than LDL-C in post-PCI patients on statin therapy.
  • Serial hs-CRP monitoring is valuable for risk stratification in this population.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
219
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
236
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
589
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
242